BMP AI Technologies Responds to OTC Markets Caveat Emptor Designation

BMP AI Technologies Inc. has issued a statement regarding the Caveat Emptor designation applied by OTC Markets Group on October 22, 2025. The company has been in active communication with OTC Markets to understand the basis for the designation, which relates to the review of the company's publicly available financial information and recent market activity in its securities. OTC Markets has provided the company with a detailed list of supplemental information that it has requested, and BMP AI Technologies intends to furnish all such information promptly, expecting to complete its response within the week.

The company reiterates that it has not authorized or engaged any third parties to conduct promotional, marketing, or investor relations campaigns on its behalf. BMP AI Technologies remains fully committed to transparency, regulatory compliance, and accurate disclosure, and is cooperating fully with OTC Markets to expedite the removal of the caveat emptor designation. OTC Markets has informed the company that such designations are generally maintained for a 30-day period; however, under the circumstances, the company and its legal counsel will be requesting that the 30-day policy be waived and that the designation be removed upon verification of the requested supplemental information.

A spokesperson for BMPA stated that the company is aware of the designation and is taking this matter very seriously, with the team fully committed to cooperating with OTC Markets and ensuring compliance. The company confirms that its operations and SEC filings remain current, with additional information about BMP AI Technologies Inc. available at https://www.bmpaitech.com or by visiting https://www.sec.gov. The company will continue to keep shareholders informed as it works through this process with OTC Markets Group.